The U.S. Food and Drug Administration has approved a fixed-duration combination treatment comprising Venclexta and Calquence for patients with previously untreated chronic lymphocytic leukemia (CLL), marking the first all-oral regimen option for this patient population. The approval was supported by data from the Phase 3 AMPLIFY trial, which demonstrated clinical efficacy compared to standard chemotherapy approaches.
According to trial results, 77% of patients receiving the combination therapy achieved progression-free survival at the three-year mark, compared to 67% in the chemotherapy control arm. The regimen demonstrated a 35% reduction in the risk of disease progression or death relative to the standard treatment option, providing quantifiable benefit for this patient segment.
The approval represents an important treatment advancement for CLL management, offering patients an oral alternative to traditional chemotherapy with defined treatment duration. This development may influence treatment selection for early-stage disease, particularly among patients who may benefit from avoiding intravenous administration.